Developmental Funds continue to represent an important and critical institutional resource to support newly recruited faculty without prior peer-reviewed support into the 19 Basic Science, Clinical and Populationbased Research Programs of MDACC, to develop new shared resources in response to the research needs of peer-reviewed investigators, and to support multidisciplinary research programs. A significant increase in Developmental Funds is requested in this competitive renewal based on the institution's careful stewardship and successful return on the funds invested in newly recruited faculty during the current grant period, the plans for the Monoclonal Antibody Facility, Molecular Cytogenetics Facility, Immune Monitoring Core Laboratory, and the pilot projects of the Multidisciplinary Research Programs. Processes are in place within the institution to solicit proposals for support from CCSG Developmental Funds and to review them for scientific merit and programmatic relevance. The Developmental Funds requested will be leveraged with institutional resources to insure the scientific growth and excellence of MDACC's research programs, including the continued recruitment of outstanding new junior faculty, the ability to provide the necessary shared resource infrastructure to support research initiatives, and the flexibility to capitalize on new and innovative research leads. The Developmental Funds will provide the Director of the Cancer Center with a stable source of support for a variety of activities critical to maintaining the research strength and interactive environment characteristic of the MDACC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310867
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$965,415
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Smith, Brian; Hsu, Yi-Hsin; Flores, Rene et al. (2018) Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy. Am J Cancer Res 8:183-191
Kuerer, Henry M; Rauch, Gaiane M; Krishnamurthy, Savitri et al. (2018) A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg 267:946-951
Tamari, Roni; Oran, Betul; Hilden, Patrick et al. (2018) Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1079-1087
Khalaf, Ahmed M; Fuentes, David; Morshid, Ali I et al. (2018) Role of Wnt/?-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma 5:61-73
Horvath, Thomas D; Dagan, Shai; Lorenzi, Philip L et al. (2018) Positional stable isotope tracer analysis reveals carbon routes during ammonia metabolism of Aedes aegypti mosquitoes. FASEB J 32:466-477
Yang, Wei T; Parikh, Jay R; Stavros, A Thomas et al. (2018) Exploring the Negative Likelihood Ratio and How It Can Be Used to Minimize False-Positives in Breast Imaging. AJR Am J Roentgenol 210:301-306
Tetzlaff, M T; Messina, J L; Stein, J E et al. (2018) Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol 29:1861-1868
Yan, Xiaoyu; Clemens, Pamela L; Puchalski, Thomas et al. (2018) Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet 57:529-538
Jacobs, Daniel I; Liu, Yanhong; Gabrusiewicz, Konrad et al. (2018) Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. J Neurooncol 136:33-39
Kato, Shumei; Jardim, Denis L; Johnson, Faye M et al. (2018) Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs 36:416-423

Showing the most recent 10 out of 12418 publications